FDA Approves First Treatment for Rare Barth Syndrome

TL;DR Summary
The FDA has granted accelerated approval to Forzinity (elamipretide) as the first treatment for Barth syndrome, a rare and serious mitochondrial disease, based on improvements in muscle strength that are likely to benefit patients, with further studies required to confirm these benefits.
- FDA Grants Accelerated Approval to First Treatment for Barth Syndrome fda.gov
- FDA greenlights Stealth Bio’s injection as 1st treatment for Barth syndrome Fierce Pharma
- FDA approves ultra-rare disease drug that became a symbol of uncertainty over regulatory standards statnews.com
- Orland Park baby's treatment for rare genetic disease Barth Syndrome granted accelerated approval by Food and Drug Administration ABC7 Chicago
- A rare disease exhausted him. A drug gives him energy to fight for others. AJC.com
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
2 min
vs 3 min read
Condensed
90%
442 → 42 words
Want the full story? Read the original article
Read on fda.gov